Elevated serum KL-6 levels in patients with systemic sclerosis: Association with the severity of pulmonary fibrosis

Dermatology

Volumn 200, Issue 3, 2000, Pages 196-201

  Sato, Shinichi ^a   Nagaoka, T ^a   Hasegawa, M ^a   Nishijima, C ^a   Takehara, K ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

KL 6; Pulmonary fibrosis; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE; DIFFERENTIATION ANTIGEN; KL 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; SEROLOGY; SYSTEMIC SCLEROSIS; VITAL CAPACITY;

EID: 0034098833     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000018382     Document Type: Article

References (28)

1. Steen VD, Conte C, Owens GR, Medsger TA: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-1289.
2. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M: Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988;18:203-216.
3. Stahel RA, Gilks WR, Lehmann HP, Schenker T: Third international workshop on lung tumor and differentiation antigens: Overview of the results of the central data analysis. Int J Cancer 1994;8:6-26.
4. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity: Sialylated carbohydrate antigen KL-6. Chest 1989; 96:68-73.
5. Kobayashi J, Kitamura S: KL-6: A serum marker for interstitial pneumonia. Chest 1995; 108:311-315.
6. Kohno N, Hamada H, Fujioka S, Hiwada K, Yamakido M, Akiyama M: Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest 1992;102:117-122.
7. Hamada H, Kohno N, Akiyama M, Hiwada K: Monitoring of serum KL-6 antigen in patients with radiation pneumonia. Chest 1992;101: 858-860.
8. Hamada H, Kohno N, Yokoyama A, Hirasawa Y, Hiwada K, Sakatani M, Ueda E: KL-6 as a serologic indicator of Pneumocystic carinii pneumonia in immunocompromised hosts. Int Med 1998;37:307-310.
9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-590.
10. LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N, Jablonska S, Wollheim F: Scleroderma (systemic sclerosis): Classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-205.
11. Steen VD, Powell DL, Medsger TAJ: Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
12. Sato S, Ihn H, Kikuchi K, Takehara K: Antihistone antibodies in systemic sclerosis: Association with pulmonary fibrosis. Arthritis Rheum 1994;37:391-394.
13. 2-GPI) in systemic sclerosis. Clin Exp Immunol 1996;105: 475-479.
14. Tomita T, Takada N; Pulmonary function test; in Kanai I, Kanai M (eds): Kanai's Manual of Clinical Laboratory Medicine. Tokyo, Kanehara, 1998, pp 1739-1762.
15. Sato S, Ihn H, Soma Y, Igarashi A, Tamaki T, Kikuchi K, Ishibashi Y, Takehara K: Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum 1993;36:1137-1141.
16. Kobayashi J, Itoh Y. Kitamura S, Kawai T: Establishment of reference intervals and cut-off value by an enzyme immunoassay for KL-6 antigen, a new marker for interstitial pneumonia. Jpn J Clin Pathol 1996;44:653-658.
17. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y, Yokoyama A, Hamada H, Fujioka S, Hiwada K: KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993;148:637-642.
18. Silver RM: Clinical problems: The lungs. Rheum Dis Clin North Am 1996;22:825-840.
19. Papiris SA, Vlachoyiannopoulos PG, Maniati MA, Karakostas KX, Constantopoulos SH, Moutsopoulos HH: Idiopathic pulmonary fibrosis and pulmonary fibrosis in diffuse systemic sclerosis: Two fibrosis with different prognosis. Respiration 1997;64:81-85.
20. Sato S: Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 1999;11:503-507.
21. Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K, Takehara K: Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: Enhancement by inflammatory cytokines. Br J Rheumatol 1997;36:1270-1275.
22. Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K: Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 1998;37:1188-1192.
23. Hasegawa M, Sato S, Takehara K: Augmented production of chemokines (MCP-1, MIP-1a, and MIP-1b) in patients with systemic sclerosis: MCP-1 and MIP-1a may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999;117:159-165.
24. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum tumor necrosis factor-α levels in patients with systemic sclerosis: Association with pulmonary fibrosis. J Rheumatol 1997;24:663-665.
25. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K: Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998;25:308-313.
26. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K: Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998;139:1049-1051.
27. Cox D, Earle L, Jimenez SA, Leiferman KM, Gleich GJ, Varga J: Elevated levels of eosinophil major basic protein in the sera of patients with systemic sclerosis. Arthritis Rheum 1995; 38:939-945.
28. Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K: Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 1994; 31:567-571.